期刊
HUMAN VACCINES & IMMUNOTHERAPEUTICS
卷 10, 期 6, 页码 1734-1746出版社
TAYLOR & FRANCIS INC
DOI: 10.4161/hv.28462
关键词
HIV-1; vaccine; correlates; clinical trial; efficacy; public health; licensure
资金
- US Army Medical Research and Materiel Command (USA MRMC) [Y1-AI-2642-12]
- National Institutes of Allergy and Infectious Diseases [Y1-AI-2642-12]
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. [W81XWH-07-2-0067]
- US Department of Defense (DOD) [W81XWH-07-2-0067]
The development of a safe and effective preventive HIV-1 vaccine remains a public health priority. Despite scientific difficulties and disappointing results, HIV-1 vaccine clinical development has, for the first time, established proof-of-concept efficacy against HIV-1 acquisition and identified vaccine-associated immune correlates of risk. The correlate of risk analysis showed that IgG antibodies against the gp120 V2 loop correlated with decreased risk of HIV infection, while Env-specific IgA directly correlated with increased risk. The development of vaccine strategies such as improved envelope proteins formulated with potent adjuvants and DNA and vectors expressing mosaics, or conserved sequences, capable of eliciting greater breadth and depth of potentially relevant immune responses including neutralizing and non-neutralizing antibodies, CD4+ and CD8+ cell-mediated immune responses, mucosal immune responses, and immunological memory, is now proceeding quickly. Additional human efficacy trials combined with other prevention modalities along with sustained funding and international collaboration remain key to bring an HIV-1 vaccine to licensure.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据